Categories
Connect with us on LinkedIn
AI in eCOA: Machine Translation — The Good, The Bad and The Unknown
AI is being applied to eCOA localization, but most teams are still figuring out where it genuinely helps...
Where PRO strategy goes wrong: therapeutic area fit, capture frequency, and the implementation gap that takes years to surface
Expert insights on PRO data, regulatory uncertainty, and the implementation gap that kills most ePRO strategies. Watch the...
The eCOA Iceberg: uncovering the hidden costs of software-only models
SaaS eCOA looks cheaper on paper. This guide exposes five hidden costs that change the full-service vs. software-only...
The Temporal Conundrum: Bridging the Gap Between Manual UAT and AI Automation in eCOA
Manual eCOA UAT runs 12-16 weeks because time-dependent protocol logic has to be tested across the full span...
Leveraging the patient voice to reduce regulatory uncertainty during submission
Learn how PRO data closes evidence gaps in FDA and EMA submissions. Join outcomes expert Ari Gnanasakthy and...
The ePRO blueprint for pain trials: Optimizing data capture from protocol design to efficacy endpoints
The 11-point electronic Numeric Rating Scale (eNRS) is now the preferred digital standard for BYOD pain trials, recommended...
Better Evidence Starts with Better Infrastructure
Meet Castor at ISPOR US 2026 | May 17-20 | Philadelphia, PA
Schedule a meeting with the Castor team at ISPOR US 2026. See Castor Catalyst AI for real-world evidence...
Castor adds nearly 10 commercial Phase II/III eCOA studies in H2 2025
Nearly 10 Phase II/III eCOA studies and 12 validated instruments across four therapeutic areas. Castor’s H2 2025 platform...
Castor Professional Services: Expert Clinical Study Builds
Castor’s Professional Services team offers end-to-end support for clinical trial implementation, including EDC build, eCOA, and data management....
The real-time monitoring dilemma
Offline eCOA capability creates regulatory tension with EMA device-as-source requirements while eliminating real-time monitoring capabilities that drive 80-95%...
SCOPE 2026 Meet us at Booth #1612
February 2nd – 5th | Rosen Shingle Creek in Orlando, Florida
Join Castor at SCOPE US 2026, February 2-5 at Orlando's Rosen Shingle Creek. Discover how our "self-driving" clinical...
Is Your eCOA UAT Stuck in Time?
Modern clinical trials increasingly rely on complex, time-sensitive logic within eCOA systems, such as narrow compliance windows and...
The End of the “PRO Tax”: Top 10 Commercial PROs & their cost-effective alternatives
The clinical trial industry faces a "PRO Tax"—the high costs and operational delays associated with licensing and implementing...
The Silent Saboteurs: Why Rater Drift and Site Unpreparedness Cost CNS Trials More
CNS trials fail not from technology limitations but organizational factors. Research reveals 55% of sites lack adequate eCOA...
Hospital-Based eCOA Implementation: Real Challenges in Infectious Disease Trials
Hospital-based infectious disease trials face unique eCOA implementation challenges including IT security delays, staff turnover, and patient acuity...
The Patient Experience Paradox: eCOA Strategy Overhaul
Discover how the EMA’s new Patient Experience Data (PED) guidance and the EU HTA Regulation are reshaping evidence...
On-site ePRO in Action: A Recap of Castor’s Product Spotlight
Castor’s on-site ePRO adds in-clinic PRO capture to the ePRO/CDMS workflow you already use. Staff use a site...
EQ-5D in European Trials: When Generic QoL Measures Actually Matter
Analysis of 735 FDA drug approvals reveals 0% EQ-5D labeling inclusion, while European HTA bodies demonstrate 18% technology...
Connect with us on LinkedIn
